PHYTOCANN-GROUP
On December 29, 2022, the Council of State announced the definitive authorization of the sale of CBD flowers in France. To celebrate the end of a protracted battle, CBD.fr will be offering one of its customers buying a product from its website, CBD.fr, between January 17 and April 20, 2023, the chance to win their own weight in CBD flowers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005347/en/
Gagne ton poids en weed (Photo: CBD.fr)
Following the purchase of CBD.fr in October 2022 by Phytocann Group and the reversal of the ban, CBD.fr can now devote itself fully to developing on national territory.
Current leader in online CBD sales, with more than 500 products available, CBD.fr brings together the most well-known brands in France in varied areas such as: CBD oils, CBD flowers, CBD resins, CBD for animals, and more. At the same time, CBD.fr is developing its franchise network with the goal of opening 400 shops across France by 2026. Since January 1, 18 CBD Shops have already started opening.
"This decision by the Council of State does a great deal to reassure our entire industry. It marks a huge step forward and, to celebrate this, we are organizing the hottest competition ever held in the cannabis world. Purchases made from January 1 onward will be eligible. In addition to the contest, we also want to raise awareness and contribute, in our own way, to the purchasing power of French people in our sector by offering high-quality products that are affordable for all. There is also a social aspect that we are all concerned about."
Alexandre Lacarré, Founder of Phytocann Group
April 20, 2023, the day on which the winner will be announced, is not just a random date. Find out who has won at 4.20 pm on 420 Day, or International Cannabis Day!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005347/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Second Front Systems Announces 10 Customers Prepared to Deploy on AWS European Sovereign Cloud via Game Warden® Platform3.12.2025 14:30:00 CET | Press release
Unlocks opportunity for Second Front customers to support European nations with strict data sovereignty requirements. Second Front Systems (2F), a Technology Partner in the Amazon Web Services (AWS) Partner Network (APN) and Global Security and Compliance Acceleration (GSCA) Program, today announced that ten of its existing customers have prepared for deployment onto AWS European Sovereign Cloud (ESC) via its 2F Game Warden® platform. This builds on Second Front's September announcement that 2F Game Warden will serve as an on-ramp to ESC. Independent software vendors (ISVs) seeking to support European organizations face complex regulatory requirements, including Germany's C5, and the EU's Digital Operational Resilience Act (DORA) and NIS2 Directive. By leveraging 2F Game Warden, ISVs can inherit a number of controls and expedite compliance with security frameworks. This collaboration unlocks a pre-validated solution for ISVs to meet these stringent compliance requirements while maintai
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom